Group 1 - The core issue revolves around the ongoing legal disputes between the company and Jingchuan Diagnosis, stemming from the acquisition of a 56.98% stake in Jingchuan Diagnosis in 2020, which has not been resolved satisfactorily [1][2] - The company received a final judgment from the Wuhan Intermediate People's Court, which upheld the lower court's decision requiring Jingchuan Diagnosis to provide access to various corporate documents and financial reports dating back to July 21, 2020 [3] - The management of Jingchuan Diagnosis has been accused of obstructing the company's operations, leading to a suspension of production activities, which the company disputes, claiming that their actions were misrepresented [2] Group 2 - The acquisition agreement included performance commitments for Jingchuan Diagnosis, which were reportedly met, but subsequent disputes over the transfer of remaining shares have led to ongoing litigation [1][2] - The company has faced challenges in obtaining financial data from Jingchuan Diagnosis, hindering internal audits and compliance with legal obligations [2][3] - The legal proceedings highlight the complexities and risks associated with mergers and acquisitions in the healthcare sector, particularly regarding post-acquisition integration and management conflicts [1][2][3]